CY1126258T1 - Ενωσεις ινδολινονης και χρηση αυτων στη θεραπεια ινωτικων ασθενειων - Google Patents
Ενωσεις ινδολινονης και χρηση αυτων στη θεραπεια ινωτικων ασθενειωνInfo
- Publication number
- CY1126258T1 CY1126258T1 CY20231100500T CY231100500T CY1126258T1 CY 1126258 T1 CY1126258 T1 CY 1126258T1 CY 20231100500 T CY20231100500 T CY 20231100500T CY 231100500 T CY231100500 T CY 231100500T CY 1126258 T1 CY1126258 T1 CY 1126258T1
- Authority
- CY
- Cyprus
- Prior art keywords
- treatment
- indolinone compounds
- fibrous diseases
- fibrous
- diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
- C07C205/57—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Otolaryngology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15202764 | 2015-12-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1126258T1 true CY1126258T1 (el) | 2026-02-25 |
Family
ID=55068868
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20231100500T CY1126258T1 (el) | 2015-12-24 | 2023-09-18 | Ενωσεις ινδολινονης και χρηση αυτων στη θεραπεια ινωτικων ασθενειων |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US11046672B2 (enExample) |
| EP (2) | EP3722291B1 (enExample) |
| JP (1) | JP7068172B2 (enExample) |
| KR (1) | KR20180128390A (enExample) |
| CN (1) | CN109302846B (enExample) |
| AU (1) | AU2016376011B2 (enExample) |
| BR (1) | BR112018013033A2 (enExample) |
| CA (1) | CA3009778A1 (enExample) |
| CL (1) | CL2018001742A1 (enExample) |
| CO (1) | CO2018007663A2 (enExample) |
| CY (1) | CY1126258T1 (enExample) |
| DK (1) | DK3722291T3 (enExample) |
| EA (1) | EA038796B1 (enExample) |
| ES (2) | ES2956820T3 (enExample) |
| FI (1) | FI3722291T3 (enExample) |
| HR (1) | HRP20230833T1 (enExample) |
| HU (1) | HUE062784T2 (enExample) |
| IL (1) | IL260221A (enExample) |
| LT (1) | LT3722291T (enExample) |
| MX (1) | MX379859B (enExample) |
| MY (1) | MY195904A (enExample) |
| PH (1) | PH12018501575A1 (enExample) |
| PL (1) | PL3722291T3 (enExample) |
| PT (1) | PT3722291T (enExample) |
| RS (1) | RS64703B1 (enExample) |
| SG (1) | SG11201805423TA (enExample) |
| SI (1) | SI3722291T1 (enExample) |
| SM (1) | SMT202300260T1 (enExample) |
| WO (1) | WO2017109513A1 (enExample) |
| ZA (1) | ZA201804950B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2909316T3 (es) | 2015-12-24 | 2022-05-06 | Univ California | Reguladores de CFTR y métodos de uso de los mismos |
| JP7039480B2 (ja) * | 2016-03-08 | 2022-03-22 | レスピバート・リミテツド | プロテインキナーゼ阻害剤としてのインドール誘導体およびそれらの使用 |
| KR20200044873A (ko) | 2017-08-24 | 2020-04-29 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 안구 제약학적 조성물 |
| CN109678810B (zh) * | 2019-01-23 | 2022-10-28 | 南京工业大学 | 一种1,2-氧氮杂环丁烷类化合物及其制备方法与应用 |
| EP4061373A4 (en) * | 2019-11-20 | 2023-11-15 | Angion Biomedica Corp. | METHOD FOR TREATING INFLAMMATORY BOWEL DISEASE |
| CN111789842B (zh) * | 2020-08-07 | 2021-09-21 | 南开大学 | 尼达尼布在制备用于治疗炎症性肠病的药物中的应用 |
| KR102739882B1 (ko) * | 2021-04-02 | 2024-12-06 | 연세대학교 원주산학협력단 | 로베글리타존을 유효성분으로 하는 안과질환 치료용 조성물 |
| CN113200936B (zh) * | 2021-05-19 | 2022-10-21 | 南京工业大学 | 10-甲基吩噁嗪衍生物、其锆金属有机框架材料及制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA75054C2 (uk) | 1999-10-13 | 2006-03-15 | Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг | Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу |
| DE10117204A1 (de) | 2001-04-06 | 2002-10-10 | Boehringer Ingelheim Pharma | In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel |
| JP2004182726A (ja) | 2002-11-22 | 2004-07-02 | Yamanouchi Pharmaceut Co Ltd | ２−オキソインドリン誘導体 |
| US20060154939A1 (en) | 2004-12-24 | 2006-07-13 | Boehringer Ingelheim International Gmbh | Medicaments for the Treatment or Prevention of Fibrotic Diseases |
| PE20060777A1 (es) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
| CA2602389A1 (en) | 2005-07-13 | 2007-01-18 | Allergan, Inc. | Kinase inhibitors |
| EP2303841A1 (en) | 2008-07-14 | 2011-04-06 | Gilead Sciences, Inc. | Oxindolyl inhibitor compounds |
| JP7039480B2 (ja) | 2016-03-08 | 2022-03-22 | レスピバート・リミテツド | プロテインキナーゼ阻害剤としてのインドール誘導体およびそれらの使用 |
-
2016
- 2016-12-23 ES ES20162043T patent/ES2956820T3/es active Active
- 2016-12-23 AU AU2016376011A patent/AU2016376011B2/en not_active Ceased
- 2016-12-23 PL PL20162043.2T patent/PL3722291T3/pl unknown
- 2016-12-23 CA CA3009778A patent/CA3009778A1/en not_active Abandoned
- 2016-12-23 DK DK20162043.2T patent/DK3722291T3/da active
- 2016-12-23 EA EA201891506A patent/EA038796B1/ru unknown
- 2016-12-23 KR KR1020187020374A patent/KR20180128390A/ko not_active Withdrawn
- 2016-12-23 HR HRP20230833TT patent/HRP20230833T1/hr unknown
- 2016-12-23 SG SG11201805423TA patent/SG11201805423TA/en unknown
- 2016-12-23 EP EP20162043.2A patent/EP3722291B1/en active Active
- 2016-12-23 SM SM20230260T patent/SMT202300260T1/it unknown
- 2016-12-23 BR BR112018013033A patent/BR112018013033A2/pt not_active Application Discontinuation
- 2016-12-23 MY MYPI2018001087A patent/MY195904A/en unknown
- 2016-12-23 FI FIEP20162043.2T patent/FI3722291T3/fi active
- 2016-12-23 PT PT201620432T patent/PT3722291T/pt unknown
- 2016-12-23 MX MX2018007852A patent/MX379859B/es unknown
- 2016-12-23 JP JP2018533630A patent/JP7068172B2/ja not_active Expired - Fee Related
- 2016-12-23 US US16/066,043 patent/US11046672B2/en not_active Expired - Fee Related
- 2016-12-23 LT LTEP20162043.2T patent/LT3722291T/lt unknown
- 2016-12-23 ES ES16820318T patent/ES2796358T3/es active Active
- 2016-12-23 HU HUE20162043A patent/HUE062784T2/hu unknown
- 2016-12-23 RS RS20230860A patent/RS64703B1/sr unknown
- 2016-12-23 WO PCT/GB2016/054069 patent/WO2017109513A1/en not_active Ceased
- 2016-12-23 SI SI201631745T patent/SI3722291T1/sl unknown
- 2016-12-23 EP EP16820318.0A patent/EP3394048B1/en active Active
- 2016-12-23 CN CN201680082097.2A patent/CN109302846B/zh not_active Expired - Fee Related
-
2018
- 2018-06-24 IL IL260221A patent/IL260221A/en unknown
- 2018-06-25 CL CL2018001742A patent/CL2018001742A1/es unknown
- 2018-07-23 ZA ZA201804950A patent/ZA201804950B/en unknown
- 2018-07-24 PH PH12018501575A patent/PH12018501575A1/en unknown
- 2018-07-24 CO CONC2018/0007663A patent/CO2018007663A2/es unknown
-
2023
- 2023-09-18 CY CY20231100500T patent/CY1126258T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL279752A (en) | Polycyclic compounds and use thereof in the treatment of immune disorders | |
| IL283086A (en) | Use of cannabidiol in the treatment of tuberous sclerosis complex | |
| CY2024016I1 (el) | Συνθεσεις και μεθοδοι για τη θεραπευτικη αντιμετωπιση της αναιμιας | |
| IL272470A (en) | Methods and materials for assessing and treating cancer | |
| HUE054548T2 (hu) | Amino-triazolopiridin vegyületek és azok alkalmazása rák kezelésében | |
| IL259441A (en) | Materials and methods for treatment of titin-based myopathies and other titinopaties | |
| EP3359171C0 (en) | Use of akkermansia muciniphila for treating inflammatory conditions | |
| IL256166B (en) | Compounds for use in treating neuromuscular disorders | |
| PL3303632T3 (pl) | Terapeutyczne i diagnostyczne sposoby stosowane w nowotworze | |
| EP3302442C0 (en) | DOSAGE FORMS AND THEIR USE | |
| PL3157512T3 (pl) | Zastosowanie kannabidioli w leczeniu padaczki | |
| HUE061761T2 (hu) | Tetrahidropiranil-amino-pirrolopirimidinon felhasználásra BTK-által közvetített zavarok kezelésében | |
| HUE054783T2 (hu) | Pridopidin Huntington-kór kezelésében | |
| DK3142637T3 (da) | Keratin treatment formulations and methods | |
| IL260684B (en) | Treatment for modulating gut microbiota | |
| PT3481846T (pt) | 24-hidroxiesteroides 11-substituídos para utilização no tratamento de afeções relacionadas com nmda | |
| PL3503890T3 (pl) | Stosowanie pridopidyny w leczeniu dystonii | |
| LT2945642T (lt) | Faktoriaus 1 baltymas, skirtas naudoti ligų gydymui arba prevencijai | |
| HRP20180260T1 (hr) | Dimer buprenorfina i njegova uporaba u liječenju gastrointestinalnih poremećaja | |
| EP3310376A4 (en) | MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF | |
| PL3236960T3 (pl) | Fluralaner do zastosowania w leczeniu demodekozy | |
| MA50358A (fr) | Sémaglutide en thérapie médicale | |
| PL3229794T3 (pl) | Kombinacja farmaceutyczna obejmująca ponesimod i jej zastosowanie w leczeniu stwardnienia rozsianego | |
| IL256103B (en) | Compositions and methods for treating celiac sprue disease | |
| CY1127309T1 (el) | Ebselen για χρηση στη θεραπεια της νοσου meniep |